Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 8/2008

01.06.2008 | Review Article

Novel Pharmacological Approaches for Treating Tobacco Dependence and Withdrawal

Current Status

verfasst von: August R. Buchhalter, Reginald V. Fant, Jack E. Henningfield

Erschienen in: Drugs | Ausgabe 8/2008

Einloggen, um Zugang zu erhalten

Abstract

Increasing the diversity and availability of medications for the treatment of tobacco dependence and/or withdrawal, to aid in the achievement of smoking cessation, is crucial to meet the diverse needs of tobacco users. Despite a general awareness that smoking is harmful and widespread interest in smoking cessation, nearly 50 million adults in the US and 1.3 billion worldwide continue to smoke. Nicotine replacement therapies are effective in the treatment of tobacco dependence and withdrawal, but do not meet the needs of all tobacco users. Improvement of tobacco dependence and/or withdrawal treatments is likely to rely on novel pharmacological approaches that include new chemical entities and new formulations of current drugs. In addition, new indications for treating tobacco dependence and withdrawal show promise for reducing tobacco use and associated disease.
This article focuses on a range of novel pharmacological approaches for the treatment of tobacco dependence and/or withdrawal, including oral and pulmonary nicotine delivery and the following non-nicotinic medications: antidepressants, an α4β2 nicotine partial agonist, an α2-noradrenergic agonist, cytochrome P450 (CYP) 2A6 inhibitors, opioid antagonists and GABAergic medications. In addition to existing medications, this article addresses novel medications in the clinical development stage and those that have been evaluated previously. Novel medications in the clinical development stage include at least three nicotine vaccines and the cannabinoid receptor acting drug rimonabant. Medications evaluated previously include lobeline, mecamylamine and an anticholinergic drug regimen comprising atropine, scopolamine and chlorpromazine. Having not been approved by major drug regulatory authorities for the treatment of tobacco dependence and/or withdrawal, these medications have been evaluated in an experimental capacity.
Fußnoten
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literatur
1.
Mokdad AH, Mark JS, Stroup DF, et al. Actual causes of death in the United States, 2000. JAMA 2004; 291(10): 1238–45PubMedCrossRef
2.
WHO Tobacco Free Initiative. Tobacco: deadly in any form or disguise. World No Tobacco Day 2006. Geneva: World Health Organization, 2006
3.
Slama K. Current challenges in tobacco control. Int J Tuberc Lung Dis 2004; 8(10): 1160–72PubMed
4.
World Bank. Curbing the epidemic: governments and the economics of tobacco control. Washington, DC: World Bank, 1999
5.
Mackay J, Eriksen M, Shafey O. The tobacco atlas. 1st ed. Atlanta (GA): American Cancer Society, 2006
6.
WHO Tobacco Free Initiative. The role of health professionals in tobacco control. World No Tobacco Day 2005. Geneva: World Health Organization, 2005
7.
Hajek P, West R, Foulds J, et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999; 159(17): 2033–8PubMedCrossRef
8.
Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database System Rev 2004; (3): CD000146
9.
Covey LS, Sullivan MA, Johnston JA, et al. Advances in non-nicotine pharmacotherapy for smoking cessation. Drugs 2000; 59(1): 17–31PubMedCrossRef
10.
Hughes JR, Goldstein MG, Hurt RD, et al. Recent advances in the pharmacotherapy of smoking. JAMA 1999; 281(1): 72–6PubMedCrossRef
11.
Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: clinical practice guideline. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service, 2000
12.
WHO Tobacco Free Initiative. Policy recommendations for smoking cessation and treatment of tobacco dependence. Geneva: World Health Organization, 2003
13.
Fant RV, Owen LL, Henningfield JE. Nicotine replacement therapy. Prim Care 1999; 26(3): 633–52PubMedCrossRef
14.
Henningfield JE, Fant RV, Buchhalter AR, et al. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 2005; 55(5): 281–99PubMedCrossRef
15.
Shiftman S, Fant RV, Buchhalter AR, et al. Nicotine delivery systems. Expert Opin Drug Deliv 2005; 2(3): 563–77CrossRef
16.
Henningfield JE, Slade J. Tobacco-dependence medications: public health and regulatory issues. Food Drug Law J 1998; 53 Suppl.: 75–114PubMed
17.
Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database System Rev 2004; (4): CD000031
18.
Jarvik ME, Henningfield JE. Pharmacological treatment of tobacco dependence. Pharmacology Biochem Behav 1988; 30(1): 279–94CrossRef
19.
Grant BF, Hasin DS, Chou SP, et al. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004; 61(11): 1107–15PubMedCrossRef
20.
Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults: United States, 2004. MMWR Morb Mortal Wkly Rep 2005; 54(44): 1121–4
21.
Comprehensive Drug Abuse Prevention and Control Act Pub. L. No. 91-513, 84 Stat. 1236 (1970) (codified as amended at 21 U.S.C. §§ 801-966)
22.
Henningfield JE, Zeller M. Could science-based regulation make tobacco products less addictive? Yale J Health Policy Law Ethics 2002; 3(1): 127–38PubMed
23.
Mansbach RS, Feltner DE, Gold LH, et al. Incorporating the assessment of abuse liability into the drug discovery and development process. Drug Alcohol Depend 2003; 70 (3 Suppl.): S73–85PubMedCrossRef
24.
Sapienza FL. Abuse deterrent formulations and the Controlled Substances Act (CSA). Drug Alcohol Depend 2006; 83 Suppl. 1: S23–30PubMedCrossRef
25.
D’Orlando KJ, Fox BS. Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw, a novel nicotine replacement product. Nicotine Tob Res 2004; 6(1): 63–70PubMedCrossRef
26.
Westman EC, Tomlin KF, Perkins CE, et al. Oral nicotine solution for smoking cessation: a pilot tolerability study. Nicotine Tob Res 2001; 3(4): 391–6PubMedCrossRef
27.
Henningfield JE, Fant RV, Gitchell J, et al. Tobacco dependence: global public health potential for new medications development and indications. Ann N Y Acad Sci 2000; 909: 247–56PubMedCrossRef
28.
Warner KE, Slade J, Sweanor DT. The emerging market for long-term nicotine maintenance. JAMA 1997; 278(13): 1087–92PubMedCrossRef
29.
Warner KE, Peck CC, Woosley RL, et al. Treatment of tobacco dependence: innovative regulatory approaches to reduce death and disease: preface. Food Drug Law J 1998; 53 Suppl.: 1–8PubMed
30.
Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and anxiety disorders. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill, 2001: 447–83
31.
Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295(1): 321–7PubMed
32.
Damaj MI, Carroll FI, Eaton JB, et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 2004; 66(3): 675–82PubMedCrossRef
33.
Cryan JF, Bruijnzeel AW, Skjei KL, et al. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) 2003; 168(3): 347–58CrossRef
34.
Bruijnzeel AW, Markou A. Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse 2003; 50(1): 20–8PubMedCrossRef
35.
Nomikos GG, Damsma G, Wenkstern D, et al. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 1989; 2(4): 273–9PubMedCrossRef
36.
Nomikos GG, Damsma G, Wenkstern D, et al. Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 1992; 7(1): 7–14PubMed
37.
Rauhut AS, Dwoskin LP, Bardo MT. Tolerance does not develop to the decrease in nicotine self-administration produced by repeated bupropion administration. Nicotine Tob Res 2005; 7(6): 901–7PubMedCrossRef
38.
Scharf D, Shiffman S. Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR. Addiction 2004; 99(11): 1462–9PubMedCrossRef
39.
Lerman C, Niaura R, Collins BN, et al. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav 2004; 18(4): 362–6PubMedCrossRef
40.
Shiffman S, Johnston JA, Khayrallah M, et al. The effect of bupropion on nicotine craving and withdrawal. Psycho-pharmacology (Berl) 2000; 148(1): 33–40CrossRef
41.
Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation: a review. Nicotine Tob Res 2005; 7(4): 491–9PubMedCrossRef
42.
Hall SM, Reus VI, Munoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55(8): 683–9PubMedCrossRef
43.
Prochazka AV, Weaver MJ, Keller RT, et al. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998; 158(18): 2035–9PubMedCrossRef
44.
Prochazka AV, Kick S, Steinbrunn C, et al. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004; 164(20): 2229–33PubMedCrossRef
45.
Wagena EJ, Knipschild P, Zeegers MP. Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction 2005; 100(3): 317–26PubMedCrossRef
46.
Kotlyar M, Golding M, Hatsukami DK, et al. Effect of nonnicotine pharmacotherapy on smoking behavior. Pharmacotherapy 2001; 21(12): 1530–48PubMedCrossRef
47.
Fulton B, Benfield P. Moclobemide: an update of its pharmacological properties and therapeutic use. Drugs 1996; 52(3): 450–74PubMedCrossRef
48.
Berlin I, Said S, Spreux-Varoquaux O, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995; 58(4): 444–52PubMedCrossRef
49.
Fowler JS, Volkow ND, Wang GJ, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996; 379(6567): 733–6PubMedCrossRef
50.
Fowler JS, Volkow ND, Wang GJ, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A 1996; 93(24): 14065–9PubMedCrossRef
51.
Cinciripini PM, Tsoh JY, Wetter DW, et al. Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. Exp Clin Psychopharmacol 2005; 13(4): 282–92PubMedCrossRef
52.
Schatzberg AF. New indications for antidepressants. J Clin Psychiatry 2000; 61 Suppl. 11: 9–17
53.
Cinciripini P, Wetter D, Tomlinson G, et al. The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob Res 2004; 6(2): 229–39PubMedCrossRef
54.
Niaura R, Spring B, Borrelli B, et al. Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. J Consult Clin Psychol 2002; 70(4): 887–96PubMedCrossRef
55.
Saules KK, Schuh LM, Arfken CL, et al. Double-blind placebo-controlled trial of fluoxetine in smoking cessation treatment including nicotine patch and cognitive-behavioral group therapy. Am J Addict 2004; 13(5): 438–46PubMedCrossRef
56.
Blondal T, Gudmundsson LJ, Tomasson K, et al. The effects of fluoxetine combined with nicotine inhalers in smoking cessation: a randomized trial. Addiction 1999; 94(7): 1007–15PubMedCrossRef
57.
Spring B, Wurtman J, Wurtman R, et al. Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. Am J Clin Nutr 1995; 62(6): 1181–7PubMed
58.
Pomerleau OF, Pomerleau CS, Morrell EM, et al. Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake. Psychoneuroendocrinology 1991; 16(5): 433–40PubMedCrossRef
59.
Killen JD, Fortmann SP, Schatzberg AF, et al. Nicotine patch and paroxetine for smoking cessation. J Consult Clinl Psycol 2000; 68(5): 883–9CrossRef
60.
The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. JAMA 1996; 275(16): 1270–80CrossRef
61.
Pfizer. Pfizer’s CHANTIX™ (varenicline) now available to help smokers quit [press release]. 2006 Aug 2. Pfizer [online]. Available from URL: http://​www.​pfizer.​com/​news/​press_​re leases/pfizer_press_release_archive.jsp [Accessed 2008 Mar 6]
62.
Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research approval package for: application number NDA 21-928. Approval letters. FDA [online]. Available from URL: http:// www.fda.gov/cder/foi/nda/2006/021928_s000_Chantix_Appr ov.pdf [Accessed 2008 Mar 7]
63.
Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 2006; 70(3): 801–5PubMedCrossRef
64.
Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48(10): 3474–7PubMedCrossRef
65.
Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 2006; 166(15): 1553–9PubMedCrossRef
66.
Rollema H, Coe JW, Chambers LK, et al. Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation. Trends Pharmacol Sci 2007; 28(7): 316–25PubMedCrossRef
67.
Gonzales D, Rennard SI, Billing CB, et al. A pooled analysis of varenicline, an alpha 4 beta 2 nicotinic receptor partial agonist versus bupropion, and placebo, for smoking cessation [PA9-2]. Society for Research on Nicotine and Tobacco 12th Annual meeting; 2006 Feb 15–18; Orlando (FL)
68.
Reeves KR, Watsky E, Williams K, et al. The safety of varenicline in cigarette smokers following a 52-week treatment period [RPOS3-54]. Society for Research on Nicotine and Tobacco 12th Annual meeting; 2006 Feb 15–18; Orlando (FL)
69.
Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alchohol Depend 1988; 21(3): 253–9CrossRef
70.
Mayo-Smith MF. Management of alcohol intoxication and withdrawal. In: Graham AW, Schultz TK, editors. Principles of addiction medicine. 2nd ed. Chevy Chase (MD): American Society of Addiction Medicine, Inc., 1998
71.
Glassman AH, Stetner F, Walsh BT, et al. Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial. JAMA 1988; 259(19): 2863–6PubMedCrossRef
72.
Glassman AH, Covey LS, Dalack GW, et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 1993; 54(6): 670–9PubMedCrossRef
73.
Hilleman DE, Mohiuddin SM, Delcore MG, et al. Randomized, controlled trial of transdermal clonidine for smoking cessation. Ann Pharmacother 1993; 27(9): 1025–8PubMed
74.
Benowitz NL, Jacob III P, Fong I, et al. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994; 268(1): 296–303PubMed
75.
Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997; 282(3): 1608–14PubMed
76.
Tyndale RF, Sellers EM. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos 2001; 29(4 Pt 2): 548–52PubMed
77.
Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine’s oral bioavailability and decreases smoking. Clin Pharmacol Ther 2000; 68(1): 35–43PubMedCrossRef
78.
Gorelick DA, Rose J, Jarvik ME. Effect of naloxone on cigarette smoking. J Subst Abuse 1988; 1(2): 153–9PubMedCrossRef
79.
80.
Wewers ME, Dhatt R, Tejwani GA. Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology (Berl) 1998; 140(2): 185–90CrossRef
81.
Covey LS, Glassman AH, Stetner F. Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis 1999; 18(1): 31–40PubMedCrossRef
82.
Markou A, Koob GF, Henningfield JE. Background paper on the neurobiology of nicotine addiction. International Tobacco Evidence Network; 2003 Sep 22–23; Mumbai
83.
Sutherland G, Stapleton JA, Russell MA, et al. Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology (Berl) 1995; 120(4): 418–25CrossRef
84.
Nemeth-Coslett R, Griffiths RR. Naloxone does not affect cigarette smoking. Psychopharmacology (Berl) 1986; 89(3): 261–4CrossRef
85.
Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49(11): 876–80PubMedCrossRef
86.
Houtsmuller EJ, Clemmey PA, Sigler LA, et al. Effects of naltrexone on smoking and abstinence. In: Harris LS, editor. NIDA research monograph 174. Problems of drug dependence 1996: proceeding of the 58th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Rockville (MD): National Institutes of Health, 1997: 68
87.
88.
Fallon JH, Moore RY. Catecholamine innervation of the basal forebrain: IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J Comp Neurol 1978; 180(3): 545–80
89.
Walaas I, Fonnum F. The distribution and origin of glutamate decarboxylase and choline acetyltransferase in ventral pallidum and other basal forebrain regions. Brain Res 1979; 177(2): 325–36PubMedCrossRef
90.
Sugita S, Johnson SW, North RA. Synaptic inputs to GABAA and GABAB receptors originate from discrete afferent neurons. Neurosci Lett 1992; 134(2): 207–11PubMedCrossRef
91.
Klitenick MA, DeWitte P, Kalivas PW. Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA: an in vivo microdialysis study. J Neurosci 1992; 12(7): 2623–32PubMed
92.
Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2000; 2(1): 19–37PubMedCrossRef
93.
Yim CY, Mogenson GJ. Electrophysiological studies of neurons in the ventral tegmental area of Tsai. Brain Res 1980; 181(2): 301–13PubMedCrossRef
94.
Kalivas PW, Churchill L, Klitenick MA. GABA and enkephalin projection from the nucleus accumbens and ventral pallidum to the ventral tegmental area. Neuroscience 1993; 57(4): 1047–60PubMedCrossRef
95.
Markou A, Paterson NE, Semenova S. Role of gamma-aminobutyric acid (GABA) and metabotropic glutamate receptors in nicotine reinforcement: potential pharmacotherapies for smoking cessation. Ann N Y Acad Sci 2004; 1025: 491–503PubMedCrossRef
96.
Dewey SL, Brodie JD, Gerasimov M, et al. A pharmacologic strategy for the treatment of nicotine addiction. Synapse 1999; 31(1): 76–86PubMedCrossRef
97.
Haney M, Hart CL, Foltin RW. Effects of baclofen on cocaine self-administration: opioid- and nonopioid-dependent volunteers. Neuropsychopharmacology 2006; 31(8): 1814–21PubMedCrossRef
98.
Roberts DC. Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction. Physiol Behav 2005; 86(1–2): 18–20PubMedCrossRef
99.
Fattore L, Cossu G, Martellotta MC, et al. Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol 2002; 37(5): 495–8PubMed
100.
Paterson NE, Froestl W, Markou A. The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl) 2004; 172(2): 179–86CrossRef
101.
Cousins MS, Stamat HM, De Wit H. Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking. Nicotine Tob Res 2001; 3(2): 123–9PubMedCrossRef
102.
Medical Economics Company. Physicians’ desk reference. 54th ed. Montvale (NJ): Medical Economics Company, 2000: 2269–71
103.
White WD, Crockford D, Patten S, et al. A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. Nicotine Tob Res 2005; 7(5): 809–13PubMedCrossRef
104.
Sofuoglu M, Mouratidis M, Yoo S, et al. Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) 2005; 181(3): 504–10CrossRef
105.
Pentel PR, Malin DH, Ennifar S, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000; 65(1): 191–8PubMedCrossRef
106.
de Villiers SH, Lindblom N, Kalayanov G, et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 2002; 69(3): 247–53PubMedCrossRef
107.
Lindblom N, de Villiers SH, Kalayanov G, et al. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 2002; 69(3): 254–60PubMedCrossRef
108.
Hasman A, Holm S. Nicotine conjugate vaccine: is there a right to a smoking future? J Med Ethics 2004; 30(4): 344–5PubMedCrossRef
109.
Cerny T. Anti-nicotine vaccination: where are we? Recent Results Cancer Res 2005; 166: 167–75PubMedCrossRef
110.
Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity. Eur J Immunol 2005; 35(7): 2031–40PubMedCrossRef
111.
112.
Hatsukami DK, Rennard S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005; 78(5): 456–67PubMedCrossRef
113.
114.
115.
116.
117.
118.
119.
Black SC. Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 2004; 5(4): 389–94PubMed
120.
Cohen C, Perrault G, Voltz C, et al. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002; 13(5–6): 451–63PubMedCrossRef
121.
Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004; 6(4): 501–8PubMedCrossRef
122.
Klesges RC, Winders SE, Meyers AW, et al. How much weight gain occurs following smoking cessation? A comparison of weight gain using both continuous and point prevalence abstinence. J Consult Clin Psychol 1997; 65(2): 286–91PubMedCrossRef
123.
Klesges RC, Meyers AW, Klesges LM, et al. Smoking, body weight, and their effects on smoking behavior: a comprehensive review of the literature. Psychol Bull 1989; 106(2): 204–30PubMedCrossRef
124.
Fagerstrom K. New perspectives in the treatment of tobacco dependence. Monaldi Arch Chest Dis 2003; 60(3): 179–83PubMed
125.
Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database System Rev 2000; (2): CD000124
126.
Nemeth-Coslett R, Henningfield JE. Effects of nicotine chewing gum on cigarette smoking and subjective and physiologic effects. Clin Pharmacol Ther 1986; 39(6): 625–30PubMedCrossRef
127.
Tennant FS, Tarver AL, Rawson RA. Clinical evaluation of mecamylamine for withdrawal from nicotine dependence. In: Harris LS, editor. NIDA research monograph 49. Problems of drug dependence 1983: proceedings of the 45th Annual Scientific Meeting, the Committee on Problems of Drug Dependence Inc. Rockville (MD): US Department of Health and Human Services; Public Health Service; Alcohol, Drug Abuse, and Mental Health Administration, 1984: 239–46
128.
Medical Economics Company. Physicians’ desk reference. 54th ed. Montvale (NJ): Medical Economics Company, 2000: 1817–8
129.
Rose JE, Behm FM, Westman EC, et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 1994; 56(1): 86–99PubMedCrossRef
130.
Glover ED, Laflin MT, Schuh KJ, et al. A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. Addiction 2007; 102(5): 795–802PubMedCrossRef
131.
Bachynsky N. The use of anticholinergic drugs for smoking cessation: a pilot study. Int J Addict 1986; 21(7): 789–805PubMed
132.
Henningfield JE, Michaelides T, Sussman S. Developing treatment for tobacco addicted youth: issues and challenges. J Child Adolesc Subst Abuse 2000; 9(4): 5–26CrossRef
133.
Henningfield JE, Moolchan ET, Zeller M. Regulatory strategies to reduce tobacco addiction in youth. Tob Control 2003; 12 Suppl. 1: 114–24
134.
Moolchan ET, Ernst M, Henningfield JE. A review of tobacco smoking in adolescents: treatment implications. J Am Acad Child Adolesc Psychiatry 2000; 39(6): 682–93PubMedCrossRef
135.
Moolchan ET, Robinson ML, Ernst M, et al. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics 2005; 115(4): e407–14PubMedCrossRef
136.
Hanson K, Allen S, Jensen S, et al. Treatment of adolescent smokers with the nicotine patch. Nicotine Tob Res 2003; 5(4): 515–26PubMed
137.
Smith TA, House Jr RF, Croghan IT, et al. Nicotine patch therapy in adolescent smokers. Pediatrics 1996; 98(4 Pt 1): 659–67PubMed
138.
Roddy E, Romilly N, Challenger A, et al. Use of nicotine replacement therapy in socioeconomically deprived young smokers: a community-based pilot randomised controlled trial. Tob Control 2006; 15(5): 373–6PubMedCrossRef
139.
Killen JD, Robinson TN, Ammerman S, et al. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol 2004; 72(4): 729–35PubMedCrossRef
140.
Upadhyaya HP, Brady KT, Wang W. Bupropion SR in adolescents with comorbid ADHD and nicotine dependence: a pilot study. J Am Acad Child Adolesc Psychiatry 2004; 43(2): 199–205PubMedCrossRef
141.
US Department of Health and Human Services. Preventing tobacco use among young people: a report of the Surgeon General. Atlanta (GA): US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotioin, Office on Smoking and Health, 1994
142.
Shadel WG, Shiffman S, Niaura R, et al. Current models of nicotine dependence: what is known and what is needed to advance understanding of tobacco etiology among youth. Drug Alcohol Depend 2000; 59 Suppl. 1: S9–22PubMedCrossRef
143.
Dierker LC, Donny E, Tiffany S, et al. The association between cigarette smoking and DSM-IV nicotine dependence among first year college students. Drug Alchohol Depend 2007; 86: 106–14CrossRef
144.
Colby SM, Tiffany ST, Shiffman S, et al. Measuring nicotine dependence among youth: a review of available approaches and instruments. Drug Alcohol Depend 2000; 59 Suppl. 1: S23–39PubMedCrossRef
145.
McLellan AT, Lewis DC, O’Brien CP, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284(13): 1689–95PubMedCrossRef
146.
McLellan AT, McKay JR, Forman R, et al. Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring. Addiction 2005; 100(4): 447–58PubMedCrossRef
147.
Ferguson JA, Patten CA, Schroeder DR, et al. Predictors of 6-month tobacco abstinence among 1224 cigarette smokers treated for nicotine dependence. Addict Behav 2003; 28(7): 1203–18PubMedCrossRef
148.
Hurt RD, Lauger GG, Offord KP, et al. An integrated approach to the treatment of nicotine dependence in a medical center setting: description of the initial experience. J Gen Intern Med 1992; 7(1): 114–6PubMedCrossRef
149.
Rose JE, Behm FM, Westman EC, et al. Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res 2006; 8(1): 89–101PubMedCrossRef
150.
Schuurmans MM, Diacon AH, van B, et al. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial. Addiction 2004; 99(5): 634–40PubMedCrossRef
Metadaten
Titel
Novel Pharmacological Approaches for Treating Tobacco Dependence and Withdrawal
Current Status
verfasst von
August R. Buchhalter
Reginald V. Fant
Jack E. Henningfield
Publikationsdatum
01.06.2008
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 8/2008
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200868080-00005

Weitere Artikel der Ausgabe 8/2008

Drugs 8/2008 Zur Ausgabe

Therapy in Practice

Management of Pulmonary Arterial Hypertension Associated with Congenital Systemic-to-Pulmonary Shunts and Eisenmenger’s Syndrome

Adis Drug Evaluation

Methoxy Polyethylene Glycol-Epoetin Beta

Review Article

Improving Delivery of Aminosalicylates in Ulcerative Colitis

Leading Article

Glycoprotein IIb/IIIa Antagonists in Acute Ischaemic Stroke

Review Article

Pharmacoeconomic Evaluations in the Treatment of Non-Small Cell Lung Cancer

Leading Article

Neovascular Age-Related Macular Degeneration